The revenue increase was primarily driven by increased revenue in the company's biopharma services, clinical services, and discovery services divisions.
By analyzing EMRs and genomic data, Mendel Health believes its AI platform can identify patients for ongoing trials and help clinicians select treatments.
The firm missed analysts' expectations on both the top and bottom lines, despite a reported 20 percent increase in clinical services revenues during the quarter.
The firm said in an SEC document that it may from time to time offer common stock, preferred stock, warrants, and overallotment purchase rights and units.
The firm’s biopharma revenues increased 11 percent, while clinical service revenues grew 20 percent, and discovery service revenue increased 12 percent.
Cancer Genetics will help analyze biomarkers to identify response patient populations, as well as reflect the mechanism of action of Effector's eFT508.
The companies expect their cancer clinical trial matching system to be available to early-access partners in the second quarter.
Its CEO said the firm has a clear path to achieving profitability, and that a big-data and artificial intelligence initiative will further expand its margins.
The companies will develop biomarkers of response to Lantern's lead therapy candidates, including a potential liquid biopsy assay for its NSCLC drug Tavocept.
The US National Institutes of Health's All of Us project awarded $4.6 million to the company Color to develop a genetic counseling resource for the program.
The Times of India reports on a pilot study that used genomic testing to determine whether patients had drug-resistant tuberculosis.
New guidelines say that more women may benefit from genetic testing for hereditary breast or ovarian cancer, according to the Los Angeles Times.
In Cell this week: small proteins identified among human microbiome, role for tumor microbes in pancreatic cancer survival, and more.